-
FDA Approves Novartis Drug To Treat More Severe Form Of Multiple Sclerosis
Wednesday, March 27, 2019 - 9:15am | 369Read More...Culminating a month that saw mostly favorable FDA verdicts, Novartis AG (NYSE: NVS) announced regulatory approval for its multiple sclerosis drug. What Happened Swiss pharma giant Novartis announced Tuesday evening the FDA greenlighted its oral drug to treat adults with relapsing forms of multiple...
-
Regulatory Concern For Celgene's Ozanimod Could Be Big For Arena Pharma, Novartis
Wednesday, February 28, 2018 - 9:26am | 329Read More...Celgene Corporation (NASDAQ: CELG) shares plummeted 10 percent Tuesday evening after the U.S. Food and Drug Administration rejected its New Drug Application for ozanimod in the treatment of relapsing multiple sclerosis. What Happened In a preliminary review, the FDA found that the clinical and...
-
Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'
Thursday, February 23, 2017 - 3:06pm | 615Read More...Offering its insight into the formulary coverage of multiple sclerosis drugs for 2017, Bernstein said in a note released on Thursday it sees stabilization of formulary coverage after a year of tightening in 2016. Treatment Options MS is a neurodegenerative disease affecting young adults,...
-
Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform
Wednesday, June 29, 2016 - 1:56pm | 242Read More...Biogen Inc (NASDAQ: BIIB) has an aging MS franchise, but a solid biosimilar pipeline is sure to offset the loss of Tecfidera, Avonex and Tysabri. Bernstein's Aaron Gal initiated Biogen at outperform and set a price target of $282. The multiple sclerosis franchise has a five-year runway as...
-
Deutsche Bank Maintains Buy on Biogen Idec After European Medical Agency Announcement
Friday, January 20, 2012 - 8:11am | 162Read More...Deutsche Bank has published a research report on Biogen Idec (NASDAQ: BIIB) after the European medical agency announced its risk/benefit review of multiple-sclerosis treatment Gilenya. In the report, Deutsche Bank writes, "The review is due to concerns related to reports of sudden deaths post...
